A study of human reovirus IgG and IgA antibodies by ELISA and Western blot

Selb, B.; Weber, Bernard

doi:10.1016/0166-0934(94)90062-0

Cited by 67 publications

(50 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is highly prevalent in the general population, with 50-60% of adults testing positive for reovirus-specific antibodies. 1 The virus is currently under investigation as an anti-cancer agent, as it targets and replicates only in tumour cells with activation of the Ras signalling pathway. 2,3 This selectivity is thought to arise because Ras-activated tumour cells cannot autophosphorylate PKR in response to the virus; this prevents phosphorylation of eukaryotic initiation factor-2a, which blocks initiation of translation of viral genes in normal cells.…”

Section: Introductionmentioning

confidence: 99%

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

et al. 2008

View full text Add to dashboard Cite

Reovirus is a promising unmodified double-stranded RNA (dsRNA) anti-cancer oncolytic virus, which is thought to specifically target cells with activated Ras. Although reovirus has been tested in a wide range of preclinical models and has entered early clinical trials, it has not previously been tested for the treatment of human melanoma. Here, we show that reovirus effectively kills and replicates in both human melanoma cell lines and freshly resected tumour; intratumoural injection also causes regression of melanoma in a xenograft in vivo model. Reovirus-induced melanoma death is blocked by caspase inhibition and is dependent on constituents of the Ras/RalGEF/p38 pathway. Reovirus melanoma killing is more potent than, and distinct from, chemotherapy or radiotherapy-induced cell death; a range of inflammatory cytokines and chemokines are released by infected tumour cells, while IL-10 secretion is abrogated. Furthermore, the inflammatory response generated by reovirus-infected tumour cells causes bystander toxicity against reovirus-resistant tumour cells and activates human myeloid dendritic cells (DC) in vitro. Hence, reovirus is suitable for clinical testing in melanoma, and may provide a useful danger signal to reverse the immunologically suppressive environment characteristic of this tumour.

show abstract

Section: Introductionmentioning

confidence: 99%

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Chua et al reported that a reovirus of bat origin could cause acute respiratory disease in humans (Chua et al, 2007). Given the fact that more than 50% of people were infected by reovirus in their lifetimes, and many of the infections occurred in the early childhood (Selb & Weber, 1994;Tai at el., 2005), and there are increasing evidences indicating that reovirus can infect normal human cells in vivo and cause some mild to serious diseases like upper respiratory illnesses, meningitis in humans (Johansson et al, 1996;Schiff et al, 2007;Tyler et al, 2004); the old concept that reoviruses were "orphan" viruses, and they were not associated with any human diseases, is not true anymore, and it should be revised. Wild-type reovirus should not be considered as an oncolytic virus, and it is unlikely that reovirus could be an effective and practical anticancer agent (L. Song, 2010).…”

Section: Reovirus Is Not An Oncolytic Virusmentioning

confidence: 99%

Gene Therapy of Some Genetic Diseases by Transferring Normal Human Genomic DNA into Somatic Cells and Stem Cells from Patients

Song¹

2011

Non-Viral Gene Therapy

View full text Add to dashboard Cite

“…Reovirus is not considered a human pathogen, due to the absence of obvious symptoms, or known clinical impact during natural or experimental infection [31]. The virus seropositivity approaches 100% in adults [32].…”

Section: Reovirus -Preclinical and Clinical Studiesmentioning

confidence: 99%

Progress in oncolytic virotherapy for treatment of thyroid malignant neoplasm

Guan

Romano

Coroniti

et al. 2014

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Thyroid malignant neoplasm develops from follicular or parafollicular thyroid cells. A higher proportion of anaplastic thyroid cancer has an adverse prognosis. New drugs are being used in clinical treatment. However, for advanced thyroid malignant neoplasm such as anaplastic thyroid carcinoma, the major impediment to successful control of the disease is the absence of effective therapies. Oncolytic virotherapy has significantly progressed as therapeutics in recent years. The advance is that oncolytic viruses can be designed with biological specificity to infect, replicate and lyse tumor cells. Significant advances in virotherapy have being achieved to improve the accessibility, safety and efficacy of the treatment. Therefore, it is necessary to summarize and bring together the main areas covered by these investigations for the virotherapy of thyroid malignant neoplasm. We provide an overview of the progress in virotherapy research and clinical trials, which employ virotherapy for thyroid malignant neoplasm as well as the future prospect for virotherapy of thyroid malignant neoplasms.

show abstract

A study of human reovirus IgG and IgA antibodies by ELISA and Western blot

Cited by 67 publications

References 19 publications

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

Gene Therapy of Some Genetic Diseases by Transferring Normal Human Genomic DNA into Somatic Cells and Stem Cells from Patients

Progress in oncolytic virotherapy for treatment of thyroid malignant neoplasm

Contact Info

Product

Resources

About